Boehringer agrees to com­ply with CM­S' price ne­go­ti­a­tions over block­buster Jar­diance

Boehringer In­gel­heim said Wednes­day that it will take part in the first round of price ne­go­ti­a­tions with the Cen­ters for Medicare and Med­ic­aid Ser­vices for its block­buster type 2 di­a­betes drug Jar­diance (em­pagliflozin).

“We are com­mit­ted to en­gag­ing in open and trans­par­ent con­ver­sa­tions with CMS,” the com­pa­ny said in a writ­ten state­ment to End­points News. “We look for­ward to shar­ing de­tailed in­for­ma­tion with CMS on the val­ue of Jar­diance and to re­in­force the need to in­vest in sci­en­tif­ic med­ical in­no­va­tion for the pa­tients we serve.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER